Skip to main
LXEO

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics Inc. focuses on innovative gene therapies for hereditary and acquired diseases, catering to significant unmet medical needs, which positions the company favorably in the biopharmaceutical market. Improved clinical outcomes have been observed, with high-dose patients showing notable mean enhancements of approximately 22% in non-sustained ventricular tachycardia (NSVT) and around 14% in premature ventricular contractions (PVCs), indicating the potential efficacy of its treatments. Additionally, the anticipated regulatory alignment and the increasing patient referrals to specialized centers following therapy advancements further support a favorable long-term outlook for Lexeo Therapeutics.

Bears say

The negative outlook on Lexeo Therapeutics's stock is primarily driven by concerns regarding the reproducibility of early activity data in subsequent clinical trials, which may result in lower-than-expected functional benefits or the emergence of safety signals. Additionally, potential changes in regulatory guidance surrounding trial design, including factors such as sample size and endpoints, could lead to delays, further impacting the company's ability to progress its gene therapies. As a result, these factors collectively raise the risk of downward revisions to the company's price target.

LXEO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Buy based on their latest research and market trends.

According to 9 analysts, LXEO has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.